Regulation of mineral metabolism by lithium
- PMID: 24013758
- DOI: 10.1007/s00424-013-1340-y
Regulation of mineral metabolism by lithium
Abstract
Lithium, an inhibitor of glycogen synthase kinase 3 (GSK3), is widely used for the treatment of mood disorders. Side effects of lithium include nephrogenic diabetes insipidus, leading to renal water loss. Dehydration has in turn been shown to downregulate Klotho, which is required as co-receptor for the downregulation of 1,25(OH)2D3 formation by fibroblast growth factor 23 (FGF23). FGF23 decreases and 1,25(OH)2D3 stimulates renal tubular phosphate reabsorption. The present study explored whether lithium influences renal Klotho expression, FGF23 serum levels, 1,25(OH)2D3 formation, and renal phosphate excretion. To this end, mice were analyzed after a 14-day period of sham treatment or of treatment with lithium (200 mg/kg/day subcutaneously). Serum antidiuretic hormone (ADH), FGF23, and 1,25(OH)2D3 concentrations were determined by ELISA or EIA, renal Klotho protein abundance and GSK3 phosphorylation were analyzed by Western blotting, and serum phosphate and calcium concentration by photometry. Lithium treatment significantly increased renal GSK3 phosphorylation, enhanced serum ADH and FGF23 concentrations, downregulated renal Klotho expression, stimulated renal calcium and phosphate excretion, and decreased serum 1,25(OH)2D3 and phosphate concentrations. In conclusion, lithium treatment upregulates FGF23 formation, an effect paralleled by substantial decrease of serum 1,25(OH)2D3, and phosphate concentrations and thus possibly affecting tissue calcification.
Similar articles
-
Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment.FASEB J. 2016 Feb;30(2):994-1001. doi: 10.1096/fj.15-279943. Epub 2015 Nov 2. FASEB J. 2016. PMID: 26527066 Free PMC article.
-
In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules.Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1261-F1270. doi: 10.1152/ajprenal.00650.2017. Epub 2018 Jul 11. Am J Physiol Renal Physiol. 2018. PMID: 29993278 Free PMC article.
-
Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23).J Mol Med (Berl). 2021 May;99(5):699-711. doi: 10.1007/s00109-021-02036-8. Epub 2021 Jan 30. J Mol Med (Berl). 2021. PMID: 33517471 Free PMC article.
-
Vitamin D and type II sodium-dependent phosphate cotransporters.Contrib Nephrol. 2013;180:86-97. doi: 10.1159/000346786. Epub 2013 May 6. Contrib Nephrol. 2013. PMID: 23652552 Review.
-
Phosphate Homeostasis, Inflammation and the Regulation of FGF-23.Kidney Blood Press Res. 2018;43(6):1742-1748. doi: 10.1159/000495393. Epub 2018 Nov 30. Kidney Blood Press Res. 2018. PMID: 30504710 Review.
Cited by
-
Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC).Sci Rep. 2018 Feb 26;8(1):3590. doi: 10.1038/s41598-018-22041-1. Sci Rep. 2018. PMID: 29483574 Free PMC article.
-
Molecular mechanisms in lithium-associated renal disease: a systematic review.Int Urol Nephrol. 2016 Nov;48(11):1843-1853. doi: 10.1007/s11255-016-1352-6. Epub 2016 Jun 29. Int Urol Nephrol. 2016. PMID: 27357223 Review.
-
1,25(OH)2D3 dependent overt hyperactivity phenotype in klotho-hypomorphic mice.Sci Rep. 2016 Apr 25;6:24879. doi: 10.1038/srep24879. Sci Rep. 2016. PMID: 27109615 Free PMC article.
-
Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment.FASEB J. 2016 Feb;30(2):994-1001. doi: 10.1096/fj.15-279943. Epub 2015 Nov 2. FASEB J. 2016. PMID: 26527066 Free PMC article.
-
Impact of lithium treatment on FGF-23 serum concentrations in depressive patients.J Clin Psychopharmacol. 2014 Dec;34(6):745-7. doi: 10.1097/JCP.0000000000000163. J Clin Psychopharmacol. 2014. PMID: 24949702 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources